Results 171 to 180 of about 7,099 (210)

Letter: Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide fumarate in patients with chronic hepatitis B: More questions than an answer - author's reply. [PDF]

Clin Mol Hepatol
Hong H, Choi J.
europepmc   +1 more source

Changes in Glomerular Filtration Rate After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Fumarate for Human Immunodeficiency Virus Preexposure Prophylaxis. [PDF]

Open Forum Infect Dis
Rivera AS, Pak K, Mefford MT, Hechter RC.   +3 more
europepmc   +1 more source

[Study on the efficacy and safety profile of tenofovir alafenamide fumarate in the treatment of patients with decompensated hepatitis B cirrhosis]. [PDF]

Zhonghua Gan Zang Bing Za Zhi
Guo F, Wu X, Dou J, Ning ZH, Wang XB, Xu Q, Ji FP, Yue YH, Wang ZG, Dang SS, Wang HF, Fu Q, Zeng ST, Zuo WZ, Wang XZ.   +14 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF)

Biochemical Pharmacology, 2016
Tenofovir alafenamide (TAF) can be considered a new prodrug of tenofovir (TFV), as successor of tenofovir disoproxil fumarate (TDF). It is in vivo as potent against human immunodeficiency virus (HIV) at a 30-fold lower dose (10mg) than TDF (300mg). TAF has been approved in November 2015 (in the US and EU), as a single-tablet regimen (STR) containing ...
Erik De Clercq
exaly   +3 more sources

Effect of P-glycoprotein and Cotreatment with Sofosbuvir on the Intestinal Permeation of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide Fumarate

Pharmaceutical Research, 2023
We aimed to compare the effects of P-glycoprotein (ABCB1) on the intestinal uptake of tenofovir disoproxil fumarate (TDF), tenofovir alafenamide fumarate (TAF), and metabolites, tenofovir isoproxil monoester (TEM) and tenofovir (TFV), and to study the molecular mechanism of drug-drug interaction (DDI) between sofosbuvir (SOF) and TDF/TAF.Bidirectional ...
Martin, Huliciak, Ivona, Lhotska, Hana, Kocova-Vlckova, Veronika, Halodova, Tomas, Dusek, Filip, Cecka, Frantisek, Staud, Ivan, Vokral, Lukas, Cerveny   +8 more
openaire   +2 more sources

Tenofovir Alafenamide Fumarate: A New Tenofovir Prodrug for the Treatment of Chronic Hepatitis B Infection [PDF]

Journal of Infectious Diseases, 2017
Tenofovir alafenamide fumarate (TAF), a new prodrug of tenofovir and a potential successor of tenofovir disoproxil fumarate (TDF), has been approved in the United States and Europe for treating adolescents and adults with chronic hepatitis B infection. TAF is formulated to deliver the active metabolite to target cells more efficiently than TDF at lower
Maria Buti, Mar Riveiro-Barciela, Rafael Esteban   +2 more
exaly   +3 more sources

Tenofovir alafenamide fumarate for the treatment of HIV infection

Drugs of Today, 2016
Tenofovir alafenamide fumarate is a recently developed prodrug of tenofovir, a nucleotide analogue reverse transcriptase inhibitor with potent inhibitory activity against HIV. The utility of a previously developed tenofovir prodrug, tenofovir disoproxil fumarate, had been hampered by renal and bone mineral adverse events. Tenofovir alafenamide fumarate
R, Sampath, J, Zeuli, S, Rizza, Z, Temesgen   +3 more
openaire   +2 more sources